-- Scott Roberts
THURSDAY, March 28 (HealthDay News) -- Tecfidera (dimethyl
fumarate) capsules have been approved by the U.S. Food and Drug
Administration to treat relapsing forms of multiple sclerosis
MS is an autoimmune disease where your body mistakenly attacks
and damages the protective covering around your nerve cells.
Signals between your brain and body are slowed or blocked
altogether by this damage. Most people with the disease have
relapses, followed by periods of remission, the FDA said in a news
release. Among the most common causes of neurological disability,
the disease affects more women than men, often beginning between
the ages of 20 and 40.
Common symptoms of MS include muscle weakness and problems with
coordination and balance.
Two clinical trials of Tecfidera demonstrated that people who
took the drug had fewer MS relapses than those who took a placebo,
the agency said. Recorded side effects included a decrease in white
blood cells, flushing and gastrointestinal problems.
Tecfidera is manufactured by Biogen Idec, of Weston, Mass.
The U.S. National Library of Medicine has more about
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.